Maureen Brunt | Academic Influence

Maureen Brunt's AcademicInfluence.com Rankings

Maureen Brunt

Economics

#2918

World Rank

#3314

Historical Rank

economics Degrees

Download Badge

Economics

Maureen Brunt's Degrees

Bachelors Economics University of Melbourne

Similar Degrees You Can Earn

Best Online Bachelor's of Economics for 2024

Why Is Maureen Brunt Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Maureen Brunt was an Australian economist and academic who specialised in the field of competition law. She was Emeritus professor of Economics at Monash University. Early life and education Brunt received a degree in economics from the University of Melbourne in 1951 and a Doctor of Philosophy in industrial organization from Harvard University in 1964.

(See a Problem?)

Maureen Brunt's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial (2020) (406)
AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial. (2018) (57)
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial (2018) (36)
Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019) (2012) (14)
Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer (2021) (10)
Advanced breast cancer: diagnosis and treatment. National Institute for Health and Clinical Excellence Guideline 2009 - a solid basis for good clinical practice. (2009) (3)
Management of breast cancer Refer women to multidisciplinary breast clinics (1994) (3)
Abstract PD5-06: Effects of perioperative lapatinib in early HER2+ breast cancer - The UK EPHOS-B trial (CRUK/08/002) (2016) (3)
LONG TERM FOLLOW‐UP OF FoRT: A PHASE 3 MULTI‐CENTER PROSPECTIVE RANDOMIZED TRIAL OF RADIATION THERAPY FOR FOLLICULAR AND MARGINAL ZONE LYMPHOMA (2019) (2)
Partial breast radiotherapy after breast conservation surgery for early breast cancer: 5-year outcomes from the IMPORT LOW (CRUK/06/003) phase III randomised controlled trial (2017) (1)
16. Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomized controlled feasibility trial called MIAMI UK (NCT03514654) (2019) (1)
Abstract P3-11-09:ARISTACAT - Aromataseinhibition plus minussaracatinib asadvanced breastcancertherapy: A randomised phase II study of aromatase inhibition plus/minus the Src-inhibitor AZD0530 in post-menopausal women with advanced breast cancer (2020) (1)
PO83 ASSESSING ACUTE THROMBOPHLEBITIS DUE TO INTRAVENOUS VINORELBINE CHEMOTHERAPY IN METASTATIC BREAST CANCER (MBC) PATIENTS AT THE UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE (UHNS) (2013) (0)
Severe colitis with Docetaxel when used in combination with HER-2 receptor blocking antibodies in breast cancer patients (2016) (0)
Corrigendum to ‘VP1-2021: Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer’ (2021) (0)
Breast radiotherapy (2019) (0)
An audit of axillary clearance following positive sentinel node biopsy in patients with invasive breast cancer and the impact it has on subsequent adjuvant management (2013) (0)
Quality of life (QOL) results of the UK TACT2 trial: more intensive chemotherapy for early breast cancer (EBC) has a measurable impact on patient-reported symptoms and functioning (CRUK/05/019) (2015) (0)
148P Phase III study of everolimus or placebo in addition to adjuvant hormone therapy for high risk early breast cancer: Subgroup analysis of the UCBG UNIRAD trial (2021) (0)

This paper list is powered by the following services:

Other Resources About Maureen Brunt

en.wikipedia.org

What Schools Are Affiliated With Maureen Brunt?

Maureen Brunt is affiliated with the following schools: